Fatal Hepatotoxicity Associated with Troglitazone
The DOI matches its Crossref record.
Abstract
Letters15 December 1998Fatal Hepatotoxicity Associated with TroglitazoneAdrian Vella, MD, Piet C. de Groen, MD, and Sean F. Dinneen, MD, MScAdrian Vella, MDMayo Clinic and Foundation; Rochester, MN 55905, Piet C. de Groen, MDMayo Clinic and Foundation; Rochester, MN 55905, and Sean F. Dinneen, MD, MScMayo Clinic and Foundation; Rochester, MN 55905Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-12-199812150-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest Dr. Whitcomb's letter concerning, among other issues, hepatotoxicity associated with troglitazone [1]. According to experience in clinical trials to date, troglitazone-related hepatotoxicity is usually asymptomatic, mild, and reversible. However, clinical trial experience of drug toxicity often underestimates the prevalence and severity of adverse events observed during postmarketing use [2]. News of six deaths and one liver transplantation associated with troglitazone led to withdrawal of the product from the British market [3]. We describe another case of fatal hepatitis associated with troglitazone.An 85-year-old man with type 2 diabetes presented with severe hepatic dysfunction. ...References1. Whitcomb RW. Update in endocrinology [Letter]. Ann Intern Med. 1998; 128:871. Google Scholar2. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freed-holm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335:1016-21. Google Scholar3. Troglitazone suspended in UK after more adverse events. SCRIP. 1997; 2290:15. Google Scholar4. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998; 338:861-6. Google Scholar5. Physicians' Desk Reference. Montvale, NJ: Medical Economics Pr; 1998:2118-21. Google Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic and Foundation; Rochester, MN 55905 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByIntegrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment—A case study of troglitazoneWhat Is Pharmacoepidemiology?Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and futureHow to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and ApprovalDesign, Synthesis, Biological Activity and Molecular Dynamics Studies of Specific Protein Tyrosine Phosphatase 1B Inhibitors over SHP-2Hepatotoxicity of Cardiovascular and Antidiabetic DrugsWhat is Pharmacoepidemiology?The safety of thiazolidinedionesRole of Peroxisome Proliferator-Activated Receptor-.GAMMA. in Atherosclerosis - An Update -Improving the Reporting of Adverse Drug Reactions in the Hospital SettingImportant Elements for the Diagnosis of Drug-Induced Liver InjuryThe Role of Drug Metabolism in ToxicityDIABETES MELLITUSCurrent and novel therapies for the treatment of nonalcoholic steatohepatitisGene Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity ScreeningINVESTIGATION OF PROTEOMIC BIOMARKERS IN IN VIVO HEPATOTOXICITY STUDY OF RAT LIVER: TOXICITY DIFFERENTIATION IN HEPATOTOXICANTSCombination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitusTroglitazone and liver injury: In search of answersAcarbose treatment in liver disease: Cognitive or glycemic control?Thiazolidinediones and InsulinHepatotoxicity of thiazolidinedionesHepatotoxicity of the thiazolidinedionesTroglitazone-induced liver failure: a case studyTroglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitusTroglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in ratsEvaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction"Did This Drug Cause My Patient's Hepatitis?" and Related QuestionsDavid W. Nierenberg, MDDifferentiating members of the thiazolidinedione class: a focus on safetyTratamiento de la diabetes mellitus: objetivos generales y manejo en la práctica clínicaHepatotoxicity of thiazolidinedionesMicroscopic Analysis of Oxidative Stress in Cultured Cells. II. Transmission Electron MicroscopyOral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatmentFactors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a ThiazolidinedioneTroglitazone-Associated Hepatotoxicity Treated Successfully with SteroidsKathleen A. Prendergast, MD, Carl L. Berg, MD, and Ralph Wisniewski, MDRECENT ADVANCES IN THE PHARMACOLOGIC MANAGEMENT O
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
Grundy, S. M. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00211-8 · Cited by 610
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure
Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., & Bass, N. M. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005405526283 · Cited by 111
Metadata
- Authors
- Vella, A., de Groen, P. C., & Dinneen, S. F.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1998-12-15
- Volume
- 129
- Issue
- 12
- Pages
- 1080
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2067677086
- Cited by
- 76
- References
- 0
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatal Hepatotoxicity Associated with Troglitazone. https://app.cochat.ai/papers/10.7326/0003-4819-129-12-199812150-00032
- The paper
- Vella, A., de Groen, P. C., & Dinneen, S. F. (1998). Fatal Hepatotoxicity Associated with Troglitazone. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-12-199812150-00032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.